Shares of Rapt Therapeutics (RAPT) have gained 34.2% over the past four weeks to close the last trading session at $10.8, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$24 indicates a potential upside of 122.2%.The average comprises three short-term price targets ranging from a low of $14.00 to a high of$31.00, with a standard deviation of $8.89. While the lowest estimate ind ...